Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Magnolia Neurosciences
New York, New York, United Statesmagnolianeurosciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Magnolia Neurosciences develops novel small molecule neuroprotective therapies targeting CNS diseases and neuronal injury. Their lead programs have shown promising preclinical results in models of chemotherapy-induced neuropathy and cognitive impairment. The company aims to rapidly achieve clinical proof-of-concept for these therapies addressing significant unmet needs in neurology. No public data yet on human trial outcomes or late-stage development.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
University of Texas MD Anderson Cancer Center (co-founder/launch partner)
Beyond the preview
Go deeper on Magnolia Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magnolia Neurosciences.